Pluristem advances towards multinational Phase III trial of PLX-PAD
28 July 2016 | By Pluristem Therapeutics Inc.
Pluristem Therapeutics Inc. has today announced its intentions to conduct a Phase III trial assessing its PLX-PAD cells in recovery following surgery for femoral neck fracture, which is the most common form of hip fracture...